Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Dickinson

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Current Opinion in HIV and AIDS|April 18, 2009
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected personsLaura Dickinson, Saye Khoo, David Back
Antimicrobial Agents and Chemotherapy|December 29, 2016
Erratum for Siccardi et al., Validation of Computational Approaches for Antiretroviral Dose OptimizationMarco Siccardi, Laura Dickinson, Andrew Owen
Expert Opinion on Drug Metabolism & Toxicology|November 17, 2010
Pharmacokinetic evaluation of etravirineLaura Dickinson, Saye Khoo, David Back
Antiviral Research|August 12, 2009
Pharmacokinetics and drug-drug interactions of antiretrovirals: an updateLaura Dickinson, Saye Khoo, David Back
Antimicrobial Agents and Chemotherapy|April 6, 2016
Validation of Computational Approaches for Antiretroviral Dose OptimizationMarco Siccardi, Laura Dickinson, Andrew Owen
Drugs|December 15, 2010
Grapefruit-drug interactionsKay Seden, Laura Dickinson, Saye Khoo, et al.
Antimicrobial Agents and Chemotherapy|June 13, 2012
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing intervalAylin Yilmaz, Victoria Watson, Laura Dickinson, et al.
Plos Computational Biology|June 15, 2018
Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemesSulav Duwal, Laura Dickinson, Saye Khoo, et al.
Plos Computational Biology|January 31, 2019
Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxisSulav Duwal, Laura Dickinson, Saye Khoo, et al.
Therapeutic Drug Monitoring|May 29, 2007
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individualsLaura Dickinson, David Back, Anton Pozniak, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Current Opinion in HIV and AIDS|April 18, 2009
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected personsLaura Dickinson, Saye Khoo, David Back
Antimicrobial Agents and Chemotherapy|December 29, 2016
Erratum for Siccardi et al., Validation of Computational Approaches for Antiretroviral Dose OptimizationMarco Siccardi, Laura Dickinson, Andrew Owen
Expert Opinion on Drug Metabolism & Toxicology|November 17, 2010
Pharmacokinetic evaluation of etravirineLaura Dickinson, Saye Khoo, David Back
Antiviral Research|August 12, 2009
Pharmacokinetics and drug-drug interactions of antiretrovirals: an updateLaura Dickinson, Saye Khoo, David Back
Antimicrobial Agents and Chemotherapy|April 6, 2016
Validation of Computational Approaches for Antiretroviral Dose OptimizationMarco Siccardi, Laura Dickinson, Andrew Owen
Drugs|December 15, 2010
Grapefruit-drug interactionsKay Seden, Laura Dickinson, Saye Khoo, et al.
Antimicrobial Agents and Chemotherapy|June 13, 2012
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing intervalAylin Yilmaz, Victoria Watson, Laura Dickinson, et al.
Plos Computational Biology|June 15, 2018
Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemesSulav Duwal, Laura Dickinson, Saye Khoo, et al.
Plos Computational Biology|January 31, 2019
Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxisSulav Duwal, Laura Dickinson, Saye Khoo, et al.
Therapeutic Drug Monitoring|May 29, 2007
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individualsLaura Dickinson, David Back, Anton Pozniak, et al.
Pageof 6